Sonali M. Smith

16.4k total citations · 1 hit paper
263 papers, 6.8k citations indexed

About

Sonali M. Smith is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Sonali M. Smith has authored 263 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Pathology and Forensic Medicine, 134 papers in Oncology and 89 papers in Genetics. Recurrent topics in Sonali M. Smith's work include Lymphoma Diagnosis and Treatment (210 papers), Chronic Lymphocytic Leukemia Research (88 papers) and Viral-associated cancers and disorders (60 papers). Sonali M. Smith is often cited by papers focused on Lymphoma Diagnosis and Treatment (210 papers), Chronic Lymphocytic Leukemia Research (88 papers) and Viral-associated cancers and disorders (60 papers). Sonali M. Smith collaborates with scholars based in United States, Canada and United Kingdom. Sonali M. Smith's co-authors include Andrew M. Evens, Ranjana H. Advani, Theodore Karrison, Nathan Fowler, John Anastasi, Richard A. Larson, Richard R. Furman, Peter A. Riedell, John P. Leonard and Michelle M. Le Beau and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Sonali M. Smith

250 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2012 848 citations Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Sonali M. Smith

Since Specialization

Citations

This map shows the geographic impact of Sonali M. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonali M. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonali M. Smith more than expected).

Fields of papers citing papers by Sonali M. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonali M. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonali M. Smith. The network helps show where Sonali M. Smith may publish in the future.

Co-authorship network of co-authors of Sonali M. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Sonali M. Smith. A scholar is included among the top collaborators of Sonali M. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonali M. Smith. Sonali M. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma 2024 ·British Journal of Haematology ·Emil Kumar, Koorosh Korfi, Findlay Bewicke‐Copley, (unknown), James A. Heward, Thomas E. Witzig, (unknown), Stephen M. Ansell, (unknown), Andrew Clear, Alejo Efeyan, Michael R. Green, R. Siebert, Barrie Peck, Maria Calaminici, Jun Wang, Sonali M. Smith, Anne J. Novak, Jude Fitzgibbon, Jessica Okosun	1
2	Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda 2024 ·JCO Oncology Practice ·Bryan Valcárcel, Kerry J. Savage, Brian K. Link, John P. Leonard, Kara M. Kelly, Gita Thanarajasingam, James R. Cerhan, Barbara Pro, Leo I. Gordon, Carrie A. Thompson, Sonali M. Smith, Lindsay M. Morton	3
3	T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses 2024 ·Cancer Immunology Research ·Xiufen Chen, Jovian Yu, Girish Venkataraman, Sonali M. Smith, Mengjie Chen, Alan Cooper, (unknown), Joshua Brody, James Godfrey, Justin Kline	1
4	Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial 2024 ·Blood Advances ·Amitkumar Mehta, Leslie Popplewell, Graham P. Collins, Sonali M. Smith, Ian W. Flinn, Nancy L. Bartlett, Nilanjan Ghosh, Gal Hacohen-Kleiman, (unknown), Linda Su-Feher, (unknown), Ranjana H. Advani, Mark Roschewski	13
5	A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016 2023 ·Hematological Oncology ·Mazyar Shadman, (unknown), Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier, Ajay K. Gopal, Shaker R. Dakhil, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	1
6	Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016 2023 ·Blood ·Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad S. Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher S. Carlson, Joo Y. Song	0
7	CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition 2023 ·Journal of Clinical Oncology ·Alan Cooper, (unknown), (unknown), Girish Venkataraman, Joo Y. Song, Andrew Lytle, Gerben Duns, Jovian Yu, Nikita Kotlov, Alexander Bagaev, Brendan P. Hodkinson, Srimathi Srinivasan, Sonali M. Smith, David W. Scott, Christian Steidl, James Godfrey, Justin Kline	10
8	Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma 2023 ·Blood Advances ·Richard Burack, Hongli Li, Diana G. Adlowitz, (unknown), Lisa M. Rimsza, Mazyar Shadman, Catherine Spier, Mark Kaminski, John P. Leonard, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	6
9	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma 2022 ·Blood Advances ·Gilles Salles, Stephen J. Schuster, Martin Dreyling, (unknown), John Kuruvilla, Piers Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez Ubieto, Keith L. Davis, (unknown), Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thiéblemont, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Yucai Wang, Brian K. Link	26
10	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL 2021 ·Blood ·Peter Martin, Nancy L. Bartlett, Julio C. Chávez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, (unknown), Chengqing Wu, (unknown), María V. Revuelta, Leandro Cerchietti, John P. Leonard	21
11	Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma 2021 ·npj Genomic Medicine ·Brian C.‐H. Chiu, Chang Chen, Qiancheng You, (unknown), Girish Venkataraman, Chang Zeng, Zhou Zhang, Xiaolong Cui, Sonali M. Smith, Chuan He, Wei Zhang	12
12	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816 2020 ·Leukemia & lymphoma ·Chul S. Ha, Michael LeBlanc, Heiko Schöder, Chelsea C. Pinnix, Nancy L. Bartlett, Andrew M. Evens, Eric D. Hsi, Lisa M. Rimsza, Michael V. Knopp, Jun Zhang, John P. Leonard, Brad S. Kahl, Hongli Li, Sonali M. Smith, Louis S. Constine, Jonathan W. Friedberg	1
13	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma 2019 ·Blood Advances ·Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael LeBlanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith	15
14	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma 2018 ·Journal of Clinical Oncology ·Andrew M. Evens, Ranjana H. Advani, Irene Helenowski, Michelle A. Fanale, Sonali M. Smith, Borko Jovanovic, Gregory Bociek, Andreas K. Klein, Jane N. Winter, Leo I. Gordon, Paul A. Hamlin	96
15	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR 2018 ·Cancer ·Anna Sureda, Mei‐Jie Zhang, Peter Dreger, Jeanette Carreras, Timothy S. Fenske, Hervé Finel, Harry C. Schouten, Silvia Montoto, Stephen Robinson, Sonali M. Smith, (unknown), Mehdi Hamadani, Marcelo C. Pasquini	40
16	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis 2017 ·Biology of Blood and Marrow Transplantation ·Mehdi Hamadani, Abraham S. Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M. Smith, Jong Wook Lee, Ernesto Ayala, Nelson J. Chao, Parameswaran Hari, Javier Bolaños‐Meade, Ronald E. Gress, (unknown), Yi‐Bin Chen, Umar Farooq, Gary J. Schiller, Jean A. Yared, Anna Sureda, Timothy S. Fenske, Horatiu Olteanu	22
17	A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma 2017 ·Blood ·Peter Martin, Nancy L. Bartlett, (unknown), María V. Revuelta, Julio C. Chávez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Lei Zhang, (unknown), Chengqing Wu, John P. Leonard, Leandro Cerchietti	7
18	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial 2015 ·British Journal of Haematology ·Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz, Anne Beaven, Fausto R. Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine M. Foss, Steven M. Horwitz, Barbara Pro, Lauren Pinter‐Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose	66
19	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108 2015 ·Journal of Clinical Oncology ·Paul M. Barr, Hongli Li, Catherine Spier, Daruka Mahadevan, Michael LeBlanc, Mansoor Ul Haq, (unknown), Christopher R. Flowers, Nina D. Wagner‐Johnston, Steven M. Horwitz, Richard I. Fisher, Bruce D. Cheson, Sonali M. Smith, Brad S. Kahl, Nancy L. Bartlett, Jonathan W. Friedberg	91
20	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies breakdown → 2012 ·Journal of Clinical Oncology ·Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler	848

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact